InvestorsHub Logo

ignatiusrielly35

02/08/24 11:35 PM

#451411 RE: jav0033 #451410

Not what he said. He said another trial is a possibility but left open the possibility that the FDA might consider an NDA filing. Either way it is clearly not “ dead.”

Steady_T

02/09/24 12:20 AM

#451412 RE: jav0033 #451410

Worst case for Rett is running another trial. Setback? Possibly. Dead? Not likely.

Rubyred77

02/09/24 2:11 AM

#451416 RE: jav0033 #451410

That is NOT what the horse said. Let me quote it for you.

“That is a very good point, and it’s exactly a possibility. And again, we would not do that, however, without further get regulatory input, because we might get some feedback, which could be very favorable. But indeed, that is something which could be done very easily. It’s a 12-week study, it’s not too long. And we have, again, a strong interest from the community, given the strong interest, and to continue to stay on study drug and patients in Rett syndrome from our program have been now on this drug for over four years – up to four years. That really shows a very high sticky interest to keep our drug and not to switch to anything else in the meantime.”